Actively Recruiting
Tumor Regression Grade As Predictor of Adjuvant Therapy
Led by Fujian Medical University Union Hospital · Updated on 2024-11-29
400
Participants Needed
1
Research Sites
53 weeks
Total Duration
On this page
Sponsors
F
Fujian Medical University Union Hospital
Lead Sponsor
T
The First Affiliated Hospital of Xiamen University
Collaborating Sponsor
AI-Summary
What this Trial Is About
Neoadjuvant therapy followed by surgery is preferred for locally advanced esophageal squamous cell carcinoma, but the necessity of adjuvant therapy remains controversial. Tumor regression grade reflects the response to neoadjuvant therapy and may predict patient prognosis, yet its role in guiding adjuvant therapy remains unexplored.
CONDITIONS
Official Title
Tumor Regression Grade As Predictor of Adjuvant Therapy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Underwent R0 resection with either two-field or three-field lymphadenectomy
- Received neoadjuvant therapy such as preoperative radiotherapy, chemoradiotherapy, or combined immunotherapy
- Diagnosed with esophageal squamous cell carcinoma pathology
You will not qualify if you...
- Incomplete clinical data or follow-up information
- Diagnosed with multiple primary malignancies
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Fujian Medical University Union Hospital
Fuzhou, Fujian, China, 350001
Actively Recruiting
Research Team
M
Maohui Chen
CONTACT
Y
Yizhou Huang
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here